US 12,584,921 B2Granted

Partitioning systems and methods for determining multiple types of cancers

AssigneeCleveland Diagnostics, Inc.

InventorsArnon Chait, Boris Y. Zaslavsky

Life of this patent

Estimating the term…

Loading patent…

Abstract

The present disclosure generally relates to systems and methods for partitioning species. In some embodiments, such systems can be used for determining one or more types of cancer. For example, certain aspects are generally directed to aqueous multi-phase partitioning systems that can be used, for example, for distinguishing between different types of cancers, diagnosing subjects with cancer, or the like. In some cases, such systems can be identified using solvent properties such as the solvent dipolarity/polarizability difference (Δπ*), the solvent hydrogen bond donor acidity difference (Δα), the solvent hydrogen bond acceptor basicity difference (Δβ), and the electrostatic property difference (c) between two phases of the partitioning system. These may be within certain ranges in accordance with various embodiments.

Claims12

Dependent claims

A method, comprising:

providing at least a first aqueous two-phase partitioning system and a second aqueous two-phase partitioning system compositionally identical to the first partitioning system;
adding a first sample comprising a first cancer cell type to the first partitioning system to partition a first solute in the first sample within the first partitioning system and to partition a second solute in the first sample within the first partitioning system;
adding a second sample comprising a second cancer cell type different from the first cancer cell type to the second partitioning system to partition the first solute in the second sample within the second partitioning system and to partition the second solute in the second sample within the second partitioning system;
comparing a first partition coefficient of the first solute within the first partitioning system with a second partition coefficient of the first solute within the second partitioning system, wherein the first partition coefficient differs from the second partition coefficient;
and
comparing a third partition coefficient of the second solute within the first partitioning system with a fourth partition coefficient of the second solute within the second system, wherein the third partition coefficient of the second solute differs from the fourth partition coefficient of the second solute.

3 more elements

A method, comprising:

providing a first aqueous two-phase partitioning system;
adding a first sample comprising a first cancer cell type to the first partitioning system to partition a first solute in the sample within the first partitioning system and to partition a second solute in the sample within the first partitioning system;
and
comparing a first partition coefficient of the first solute in the first partitioning system and a second partition coefficient of the second solute within the first partitioning system with a first reference partition coefficient and a second reference partition coefficient, respectively, wherein the first reference partition coefficient is the partition coefficient of the first solute and the second reference partition coefficient is the partition coefficient of the second solute that result from the addition of a sample comprising a reference cancer cell type different from the first cancel cell type to a reference partitioning system compositionally identical to the first partitioning system,
wherein the first partition coefficient differs from the first reference partition coefficient, and
wherein the second partition coefficient differs from the second reference partition coefficient.

3 more elements

Dependencies are inferred from the claim text.

Facts

Application: 18/469,458Filed 18 Sep 2023 · continuation
Priority: 28 Oct 2021
Published: US 2024/0011995 A111 Jan 2024
Granted: 24 Mar 2026
Term ends: Not estimatedThe source records don’t support an estimate.

Classification6 codes

G01N 33/57585
Involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins,…:…
G01N 33/5002
Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing:…
G01N 33/575
Immunoassay; Biospecific binding assay; Materials therefor: for cancer
G01N 33/57557
For cancer: of other specific parts of the body, e.g. brain

Family

Application63/272,759Us provisional application · filed 28 Oct 2021
PCT/US2022/046537Parent of this continuation · filed 13 Oct 2022
US 2024/0011995 A1Pre-grant publication · published 11 Jan 2024
Application18/030,849Parent of this continuation
US 11,796,544 B1Parent of this continuation
US 2023/0314439 A1Published application
US 12,584,921 B2This patent

From the US filing history. Foreign family members aren’t listed.